ORIC Pharmaceuticals, Inc.
ORIC
Rank in Stocks
#8863
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm... ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Share Price
$9.23
Last synced: 2026-11-09
Market Cap
$956.71M
Change (1 day)
4.65%
Change (1 year)
-28.34%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade ORIC Pharmaceuticals, Inc. (ORIC)
Category
Healthcare
EPS for ORIC Pharmaceuticals, Inc. (ORIC)
EPS as of June 2026 TTM: $-1.35
According to ORIC Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-1.35. At the end of 2025 the company had an EPS of $-1.47, an increase over its 2024 EPS of $-1.83.
EPS history for ORIC Pharmaceuticals, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.35 | -8.16% |
| 2025 | $-1.47 | -19.67% |
| 2024 | $-1.83 | -6.63% |
| 2023 | $-1.96 | -12.89% |
| 2022 | $-2.25 | 8.70% |
| 2021 | $-2.07 | -38.39% |
| 2020 | $-3.36 | 140.00% |
| 2019 | $-1.40 | -88.64% |
| 2018 | $-12.32 | -21.13% |
| 2017 | $-15.62 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,260.00% |
US
|
|
| $-7.07 | 423.70% |
US
|
|
| $-5.29 | 291.85% |
AU
|
|
| $12.88 | -1,054.08% |
BE
|
|
| $21.56 | -1,697.04% |
NL
|
Questions about ORIC Pharmaceuticals, Inc.'s earnings per share (EPS)
What is ORIC Pharmaceuticals, Inc.'s earnings per share (EPS)?
ORIC Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-1.35, as of Jun 2026.
What was ORIC Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, ORIC Pharmaceuticals, Inc.'s earnings per share (EPS) was $-1.47, compared with $-1.83 in 2024.
How has ORIC Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, ORIC Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.47) and lowest in 2020 ($-3.36).
How does ORIC Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
ORIC Pharmaceuticals, Inc.'s earnings per share (EPS) ($-1.35) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.